We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline has announced an agreement with the U.S. government to provide a stockpile of its anti-viral drug in preparation for a potential influenza pandemic.
Sen. Richard Burr’s (R-N.C.) bill to strengthen the federal response to public health crises and bioterrorism is one step closer to passage after being unanimously approved in committee July 19 and is unlikely to face many obstacles in passing the Senate, a congressional staffer told DID.
The FDA seems unlikely to heed a recent HHS Office of
Inspector General (OIG) report on postmarketing reviews, opposing the report’s call for substantive changes to agency policy.
The chief of the Geriatric Psychiatry Branch at the National Institute of Mental Health faces multiple investigations into allegations he improperly received nearly $600,000 from Pfizer.
The Centers for Medicare & Medicaid Services (CMS) is developing a regulation designed to ensure an accurate calculation of average manufacturer prices (AMPs) and will not post those prices by the required July 1 deadline, according to the head of the agency.
Faulty calculations by the Centers for Medicare & Medicaid Services (CMS) could cause HHS to incorrectly adjust provider reimbursements for some drugs covered under Medicare Part B, according to a recent report by HHS’ Office of the Inspector General (OIG).
Delivery to the federal government of the anthrax vaccine being developed by VaxGen, originally expected to occur by the end of the year, now will be pushed until at least late 2007, delivering a heavy fiscal blow to the financially struggling company, a VaxGen spokesman said.
Faulty calculations by the Centers for Medicare & Medicaid Services (CMS) could cause HHS to incorrectly adjust provider reimbursements for some drugs covered under Medicare Part B, according to a recent report by HHS’ Office of the Inspector General (OIG).
More than one out of every five drugs prescribed by office-based or ambulatory care doctors — as opposed to doctors based in hospitals and other inpatient settings — is prescribed off-label, according to a study published in the May 8 issue of Archives of Internal Medicine.